In the last years, it has been demonstrated that prostate-specific membrane antigen (PSMA) plays a pivotal role in the detection, at diagnosis, of primary PCa as well as of recurrent and metastatic sites of disease, being an optimal target highly overexpressed in poorly differentiated, metastatic, and hormone-refractory PCa [2,3]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.